FAP-related desmoid tumors: A series of 44 patients evaluated in a cancer referral center

Histology and Histopathology

Volumn 27, Issue 5, 2012, Pages 641-649

  Colombo, Chiara ^a   Foo, Wai Chin ^a   Whiting, David ^a   Young, Eric D ^a   Lusby, Kristelle ^a   Pollock, Raphael E ^a   Lazar, Alexander J ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

catenin; APC; Desmoid tumors; Gardner syndrome; Targeted therapy

Indexed keywords

BETA CATENIN; CCND1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYCLIN D1; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ESTROGEN RECEPTOR BETA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PTGS2 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ABDOMINAL TUMOR; ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; COLON POLYPOSIS; FEMALE; FIBROMATOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ABDOMINAL NEOPLASMS; ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; BETA CATENIN; COHORT STUDIES; CYCLIN D1; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84859353387     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Arvanitis M.L., Jagelman D.G., Fazio V.W., Lavery I.C. and McGannon E. (1990). Mortality in patients with familial adenomatous polyposis. Dis. Colon Rectum. 33, 639-642.
2. Bertario L., Russo A., Sala P., Eboli M., Giarola M., D'Amico F., Gismondi V., Varesco L., Pierotti M.A. and Radice P. (2001). Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int. J. Cancer 95, 102-107.
3. Bonvalot S., Eldweny H., Haddad V., Rimareix F., Missenard G., Oberlin O., Vanel D., Terrier P., Blay J.Y., Le Cesne A. and Le Péchoux C. (2008). Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur. J. Surg. Oncol. 34, 462-428.
4. Bülow S., Berk T. and Neale K. (2006). The history of familial adenomatous polyposis. Fam. Cancer 5, 213-220.
5. Chugh R., Wathen J.K., Patel S.R., Maki R.G., Meyers P.A., Schuetze S.M., Priebat D.A., Thomas D.G., Jacobson J.A., Samuels B.L., Benjamin R.S. and Baker L.H.; Sarcoma Alliance for Research through Collaboration (SARC) (2010). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clin. Cancer Res.16, 4884-4891.
6. Clark S.K. and Phillips R.K. (1996). Desmoids in familial adenomatous polyposis. Br. J. Surg. 83, 1494-1504.
7. Clark S.K., Neale K., Landgrebe J.C. and Phillips R.K. (1999). Desmoid tumours complicating familial adenomatous polyposis. Br. J. Surg. 86, 1185-1189.
8. De Bree E., Keus R., Melissas J., Tsiftsis D. and van Coevorden F. (2009). Desmoid tumors: need for an individualized approach. Expert. Rev. Anticancer. Ther. 9, 525-535.
9. Durno C., Monga N., Bapat B., Berk T., Cohen Z. and Gallinger S. (2007). Does early colectomy increase desmoid risk in familiali adenomatous polyposis? Clin. Gastroenterol. Hepatol. 5, 1190-1194.
10. Fiore M., Rimareix F., Mariani L., Domont J., Collini P., Le Péchoux C., Casali P.G., Le Cesne A., Gronchi A. and Bonvalot S. (2009). Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann. Surg. Oncol. 16, 2587-2593.
11. Friedl W., Caspari R., Sengteller M., Uhlhaas S., Lamberti C., Jungck M., Kadmon M., Wolf M., Fahnenstich J., Gebert J., Möslein G., Mangold E. and Propping P. (2001). Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 48, 515-521.
12. Gardner E.J. and Richard R.C. (1953). Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am. J. Hum. Genet. 5, 139-147.
13. Gurbuz A.K., Giardiello F.M., Petersen G.M., Krush A.J., Offerhaus G.J., Booker S.V., Kerr M.C. and Hamilton S.R. (1994). Desmoid tumours in familial adenomatous polyposis. Gut 35, 377-381.
14. Half E., Bercovich D. and Rozen P. (2009). Familial adenomatous polyposis. Orphanet. J. Rare Dis. 12, 4-22.
15. Heiskanen I. and Järvinen H.J. (1996). Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int. J. Colorectal Dis.11, 157-62.
16. Knudsen A.L. and Bulow S. (2001). Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam. Cancer 1, 111-119.
17. Kotiligam D., Lazar A.J., Pollock R.E. and Lev D. (2008). Desmoid tumor: a disease opportune for molecular insights. Histol. Histopathol. 23, 117-126.
18. Lazar A.J., Tuvin D., Hajibashi S., Habeeb S., Bolshakov S., Mayordomo-Aranda E., Warneke C.L., Lopez-Terrada D., Pollock R.E. and Lev D. (2008). Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 173, 1518-1527.
19. Latchford A., Volikos E., Johnson V., Rogers P., Suraweera N., Tomlinson I., Phillips R. and Silver A. (2007). APC mutations in FAPassociated desmoid tumours are non-random but not 'just right'. Hum. Mol. Genet. 16, 78-82.
20. Lev D., Kotilingam D., Wei C., Ballo M.T., Zagars G.K., Pisters P.W., Lazar A.J., Patel S.R., Benjamin R.S. and Pollock RE. (2007). Optimizing treatment of desmoid tumors. J. Clin. Oncol. 25, 1785-1791.
21. Mendenhall W.M., Zlotecki R.A., Morris C.G., Hochwald S.N. and Scarborough M.T. (2005). Aggressive fibromatosis. Am. J. Clin. Oncol. 28, 211-215.
22. Nieuwenhuis M.H., Casparie M., Mathus-Vliegen L.M., Dekkers O.M., Hogendoorn P.C. and Vasen H.F. (2010). A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int. J. Cancer 127, 1421-1428.
23. Nieuwenhuis M.H., Mathus-Vliegen E.M., Baeten C.G., Nagengast F.M., van der Bijl J., van Dalsen A.D., Kleibeuker J.H., Dekker E., Langers A.M., Vecht J., Peters F.T., van Dam R., van Gemert W.G., Stuifbergen W.N., Schouten W.R., Gelderblom H. and Vasen H.F. (2011). Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br. J. Cancer 104, 37-42.
24. Penel N., Le Cesne A., Bui B.N., Perol D., Brain E.G., Ray-Coquard I., Guillemet C., Chevreau C., Cupissol D., Chabaud S., Jimenez M., Duffaud F., Piperno-Neumann S., Mignot L. and Blay J.Y. (2011). Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann. Oncol. 22, 452-457.
25. Rodriguez-Bigas M.A., Mahoney M.C., Karakousis C.P. and Petrelli N.J. (1994). Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 74, 1270-1274.
26. Sinha A., Tekkis P.P., Gibbons D.C., Phillips R.K. and Clark S.K. (2010). Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis. 97, 1710-1715.
27. Sleijfer S. (2009). Management of aggressive fibromatosis: can we unravel the maze of treatment options? Eur. J. Cancer 45, 2928-2929.
28. Soravia C., Berk T., Mc Leod R.S. and Cohen Z. (2000). Desmoid disease in patients with familial adenomatous polyposis. Dis. Colon Rectum. 43, 363-369.
29. Vasen H.F. (2000). Clinical diagnosis and management of hereditary colorectal cancer syndromes. J. Clin. Oncol. 18, 81S-92S.
30. Vasen H.F., Möslein G., Alonso A., Aretz S., Bernstein I., Bertario L., Blanco I., Bülow S., Burn J., Capella G., Colas C., Engel C., Frayling I., Friedl W., Hes F.J., Hodgson S., Järvinen H., Mecklin J.P., Møller P., Myrhøi T., Nagengast F.M., Parc Y., Phillips R., Clark S.K., de Leon M.P., Renkonen-Sinisalo L., Sampson J.R., Stormorken A., Tejpar S., Thomas H.J. and Wijnen J. (2008). Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57, 704-713.